Logo image of 1MRNA.MI

MODERNA INC (1MRNA.MI) Stock Fundamental Analysis

BIT:1MRNA - US60770K1079 - Common Stock

20.605 EUR
-0.63 (-2.99%)
Last: 9/8/2025, 7:00:00 PM
Fundamental Rating

3

Overall 1MRNA gets a fundamental rating of 3 out of 10. We evaluated 1MRNA against 70 industry peers in the Biotechnology industry. 1MRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 1MRNA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

1MRNA had negative earnings in the past year.
1MRNA had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: 1MRNA reported negative net income in multiple years.
In multiple years 1MRNA reported negative operating cash flow during the last 5 years.
1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCF1MRNA.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

Looking at the Return On Assets, with a value of -24.17%, 1MRNA is in line with its industry, outperforming 52.86% of the companies in the same industry.
The Return On Equity of 1MRNA (-30.89%) is better than 61.43% of its industry peers.
Industry RankSector Rank
ROA -24.17%
ROE -30.89%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
1MRNA.MI Yearly ROA, ROE, ROIC1MRNA.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

Looking at the Gross Margin, with a value of 68.32%, 1MRNA is in the better half of the industry, outperforming 64.29% of the companies in the same industry.
1MRNA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for 1MRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
1MRNA.MI Yearly Profit, Operating, Gross Margins1MRNA.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

1MRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 1MRNA has more shares outstanding
Compared to 5 years ago, 1MRNA has more shares outstanding
The debt/assets ratio for 1MRNA has been reduced compared to a year ago.
1MRNA.MI Yearly Shares Outstanding1MRNA.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
1MRNA.MI Yearly Total Debt VS Total Assets1MRNA.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

An Altman-Z score of 3.07 indicates that 1MRNA is not in any danger for bankruptcy at the moment.
1MRNA's Altman-Z score of 3.07 is fine compared to the rest of the industry. 1MRNA outperforms 75.71% of its industry peers.
1MRNA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
1MRNA has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. 1MRNA outperforms 85.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.07
ROIC/WACCN/A
WACC9.66%
1MRNA.MI Yearly LT Debt VS Equity VS FCF1MRNA.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

A Current Ratio of 3.93 indicates that 1MRNA has no problem at all paying its short term obligations.
1MRNA has a Current ratio of 3.93. This is in the better half of the industry: 1MRNA outperforms 71.43% of its industry peers.
A Quick Ratio of 3.77 indicates that 1MRNA has no problem at all paying its short term obligations.
1MRNA has a better Quick ratio (3.77) than 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 3.93
Quick Ratio 3.77
1MRNA.MI Yearly Current Assets VS Current Liabilites1MRNA.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 51.04% over the past year.
1MRNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -39.05%.
Measured over the past years, 1MRNA shows a very strong growth in Revenue. The Revenue has been growing by 122.01% on average per year.
EPS 1Y (TTM)51.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.04%
Revenue 1Y (TTM)-39.05%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-41.08%

3.2 Future

The Earnings Per Share is expected to grow by 18.49% on average over the next years. This is quite good.
Based on estimates for the next years, 1MRNA will show a quite strong growth in Revenue. The Revenue will grow by 18.60% on average per year.
EPS Next Y-7.52%
EPS Next 2Y6.31%
EPS Next 3Y12.33%
EPS Next 5Y18.49%
Revenue Next Year-40.09%
Revenue Next 2Y-18.76%
Revenue Next 3Y-6.36%
Revenue Next 5Y18.6%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
1MRNA.MI Yearly Revenue VS Estimates1MRNA.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
1MRNA.MI Yearly EPS VS Estimates1MRNA.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

1MRNA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year 1MRNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
1MRNA.MI Price Earnings VS Forward Price Earnings1MRNA.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
1MRNA.MI Per share data1MRNA.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

A more expensive valuation may be justified as 1MRNA's earnings are expected to grow with 12.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.31%
EPS Next 3Y12.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 1MRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

BIT:1MRNA (9/8/2025, 7:00:00 PM)

20.605

-0.63 (-2.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-01 2025-08-01/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners73.45%
Inst Owner ChangeN/A
Ins Owners2.56%
Ins Owner ChangeN/A
Market Cap8.02B
Analysts56
Price Target40.81 (98.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.41%
Min EPS beat(2)21.22%
Max EPS beat(2)29.6%
EPS beat(4)3
Avg EPS beat(4)36.52%
Min EPS beat(4)-6.26%
Max EPS beat(4)101.54%
EPS beat(8)6
Avg EPS beat(8)-7.95%
EPS beat(12)8
Avg EPS beat(12)0.84%
EPS beat(16)11
Avg EPS beat(16)4.98%
Revenue beat(2)1
Avg Revenue beat(2)11.48%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)23.26%
Revenue beat(4)3
Avg Revenue beat(4)17.36%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)46.04%
Revenue beat(8)7
Avg Revenue beat(8)31.8%
Revenue beat(12)9
Avg Revenue beat(12)25.64%
Revenue beat(16)12
Avg Revenue beat(16)20.85%
PT rev (1m)-4.35%
PT rev (3m)-0.83%
EPS NQ rev (1m)-6.69%
EPS NQ rev (3m)-24.05%
EPS NY rev (1m)3.5%
EPS NY rev (3m)4.3%
Revenue NQ rev (1m)-5.78%
Revenue NQ rev (3m)-22.2%
Revenue NY rev (1m)-7.3%
Revenue NY rev (3m)-8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.05
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1.01
EV/EBITDA N/A
EPS(TTM)-6.42
EYN/A
EPS(NY)-6.88
Fwd EYN/A
FCF(TTM)-7.67
FCFYN/A
OCF(TTM)-5.91
OCFYN/A
SpS6.75
BVpS20.6
TBVpS20.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.17%
ROE -30.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.32%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score4
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 386.06%
Cap/Sales 26.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.93
Quick Ratio 3.77
Altman-Z 3.07
F-Score4
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.04%
EPS Next Y-7.52%
EPS Next 2Y6.31%
EPS Next 3Y12.33%
EPS Next 5Y18.49%
Revenue 1Y (TTM)-39.05%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-41.08%
Revenue Next Year-40.09%
Revenue Next 2Y-18.76%
Revenue Next 3Y-6.36%
Revenue Next 5Y18.6%
EBIT growth 1Y35.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.85%
EBIT Next 3Y15.04%
EBIT Next 5Y19.61%
FCF growth 1Y-364.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1093.36%
OCF growth 3YN/A
OCF growth 5YN/A